末梢血単核球市場- 世界の産業規模、シェア、動向、機会、および予測、2018-2028年

世界の末梢血単核球市場は、2022年に2億3,568万米ドルと評価され、2023年から2028年の間に10.39％のCAGRで成長すると予測されています。

これは、細胞治療数の増加率、研究需要の高さ、毒性試験のための開発、製品の新規および安定的な開発を担う化合物の反応機構によるものです。例えば、2023年6月にNational Library of Medicineに掲載された研究では、トリパノソーマ・クルジのコロンビア株（Col）に試験管内で感染させ、ベンゾニダゾールで処理した末梢血単核細胞（PBMC）の免疫応答が評価されました。

トキシコロジー研究の進展

末梢血単核球に対する顧客の意識の高まりと抗体開発への嗜好の高まりは、業界の2つの重要な成長促進要因です。PBMCは、生物学的研究や病理学的研究、致死的疾患、免疫学、ワクチン開発などに関連する臨床研究を実施する上で極めて重要です。例えば、clinicaltirals.gov.inによると、末梢血単核球に関する研究は972件実施されています。PBMCは、見込みのある新薬分子が人々に及ぼす影響、特に免疫系に及ぼす影響に関する情報を提供します。PBMCに影響を及ぼす薬物毒性は、免疫系の抑制や中毒など、いくつかの深刻な、時には致命的な毒性副作用を引き起こす可能性があります。毒性学研究は、化学物質、薬物、環境因子が生物に及ぼす潜在的な有害作用を評価することを目的としています。免疫毒性研究では、これらの物質が免疫系に及ぼす影響を評価するためにPBMCが用いられます。PBMCを様々な化合物に暴露し、免疫応答を分析することにより、研究者は免疫細胞集団、サイトカイン産生、免疫機能の変化を含む免疫毒性作用を決定することができます。このように、免疫毒性研究におけるPBMCの需要は増加しており、世界の末梢血単核球市場の成長に寄与しています。

細胞療法における末梢血単核球の重要性の高まり

患者は現在、従来の再生医療に関して細胞療法に代わるより良い選択肢を手にしているが、その副作用が顧客間での使用を妨げています。この製品カテゴリーでは、北米や欧州などの先進地域が、人間の健康のための細胞療法において強い存在感を示しています。人々は、細胞治療や遺伝子治療における末梢血単核球の使用について認識を深めています。したがって、末梢血単核球の抽出と利用が市場拡大の主要な原動力であることが証明されています。しかし、急性心筋梗塞、慢性心不全、脊髄損傷、脳卒中、創傷治癒などの致死的疾患はすべて、アポトーシス末梢血単核球のセクレトームを用いた前臨床研究で治療に成功しており、これが世界の市場成長の原動力となっています。例えば、米国疾病予防管理センターによると、米国では毎年約37,300件のHPV+腫瘍が新たに発生しており、女性の悪性腫瘍全体の3％、男性の全がんの2％を占めています。米国におけるHPVの有病率の増加に伴い、企業は米国市場に参入するための治療法や薬剤の開発に継続的に注力しています。PBMCは細胞治療のための免疫細胞の貴重な供給源となります。PBMCには、T細胞、B細胞、ナチュラルキラー（NK）細胞など様々な種類の免疫細胞が含まれており、免疫反応や疾患の標的化において重要な役割を果たしています。PBMCは免疫細胞の多様な集団を提供し、それを分離、操作し、様々な細胞治療アプローチに利用することができます。

また、養子細胞移植（ACT）は細胞療法の一種であり、免疫細胞（典型的にはT細胞）を患者に移植し、がんなどの疾患を標的として排除するものです。PBMCはしばしば、腫瘍浸潤リンパ球（TIL）、腫瘍関連抗原特異的T細胞、遺伝子操作T細胞など、T細胞の特定のサブセットを分離・増幅するための出発材料として使用されます。PBMCはACT療法に便利なT細胞の供給源となります。

人類の幸福のための研究開発投資の拡大

研究開発（R&D）の実践と活動における急速な進歩は、致命的な疾患の治療のために新規の細胞/遺伝子治療/医薬品や新製品が開発されるにつれて、市場の成長を促進しています。PBMCは、日常的に採取される血液サンプルから生理学的に関連性のある（免疫）タンパク質を取得する合理的な方法であり、非常に豊富なタンパク質の存在によってもたらされるヒト血漿本来のよく知られた分析上の課題もなく、市場の成長を促進しています。さらに、ヘルスケア分野での成長のため、各国政府は末梢血単核球の継続的研究に資金を提供しています。

さらに、疾患研究におけるPBMCの可能性に対する認識の高まりが、研究開発活動の活発化につながり、市場の成長に寄与しています。PBMCは創薬や薬剤開発において重要な役割を果たしています。PBMCは、潜在的な薬剤候補の有効性と安全性を評価するための初期段階の研究に利用されています。PBMCは、免疫反応を研究し、免疫細胞に対する新規化合物の効果を評価するためのヒト関連モデルを提供します。創薬におけるPBMCの価値に対する認識の高まりは、これらの細胞の需要と利用の増加をもたらし、PBMC市場の成長を牽引しています。細胞ベースの治療法の可能性に対する認識は急速に高まっています。PBMCは、養子細胞移植、CAR-T細胞療法、免疫療法などの細胞ベースの療法の開発と製造に不可欠です。これらの高度な治療法の治療上の利点と、その開発におけるPBMCの役割に対する認識の高まりが相まって、研究開発への多大な取り組みが行われ、世界の末梢血単核球市場が成長しています。学術機関、研究機関、バイオ医薬品業界間の協力関係が顕著に増加しています。このような協力関係は、様々な研究分野におけるPBMCの応用に焦点を当てた知識交換、共同研究プロジェクト、資金提供イニシアティブを促進してきました。PBMCの可能性に対する認識の高まりと研究開発における協力的な取り組みが、世界の末梢血単核球市場の成長にプラスの影響を与えています。

利用可能なカスタマイズ

TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です：

企業情報

• 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の末梢血単核細胞市場に与える影響

第5章 顧客の声

第6章 世界の末梢血単核球市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別（凍結保存または凍結PBMC、培養または新鮮PBMC、末梢血単核球分離・生存率キット）
  • 用途別（免疫学、感染症、血液学、その他）
  • 技術別（密度勾配遠心法とロイカフェレーシス）
  • 供給源別（ヒト、動物）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2021年）
• 市場マップ
  • 製品別
  • 用途別
  • 技術別
  • ソース別
  • 地域別

第7章 北米末梢血単核球市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • ソース別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州末梢血単核球市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • ソース別
  • 国別
• 欧州国別分析
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋地域の末梢血単核球市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • ソース別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア

第10章 南米末梢血単核球市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • ソース別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカ末梢血単核球市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品別
  • 用途別
  • 技術別
  • ソース別
  • 国別
• MEA：国別分析
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

第14章 臨床試験分析

第15章 臨床試験分析競合情勢

• Competitive Outlook
• Company Profiles
  • Charles River Laboratories International, Inc.
  • Lonza Group AG
  • Corning Inc
  • Bio-Rad Laboratories Inc
  • ABCAM
  • Biolegend Inc
  • ZEN-Bio Inc
  • DAPCEL, Inc.
  • Creative Bioarray
  • iXCells Biotechnologies USA, LLC
  • Miltenyi Biotec B.V. & CO. KG
  • STEMCELL Technologies Inc.
  • Precision Medicine Group, LLC.
  • StemExpress, LLC
  • RayBiotech Life, Inc.
  • REPROCELL Inc.
  • Cytologics LLC
  • BioIVT LLC
  • Biopredic International
  • Cell Applications, Inc.

第16章 戦略的提言

第17章 TechSci Research-受賞と調査について

第18章 調査会社・免責事項

List of Figures

• Figure 1: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 2: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 3: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application Type, By Value, 2018-2028F
• Figure 4: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 5: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 6: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Region, By Value, 2018-2028F
• Figure 7: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Company, By Value, 2022
• Figure 8: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Map, By Product, Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 9: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Map, By Application, Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 10: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Map, By Technique, Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 11: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Map, By Source, By Type, Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 12: Global Peripheral Blood Mononuclear Cells Market (PBMCs) Map, By Region, Market Size (USD Billion) & Growth Rate (%), 2022
• Figure 13: North America Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 14: North America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 15: North America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 16: North America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 17: North America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 18: North America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Country, By Value, 2018-2028F
• Figure 19: United States Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 20: United States Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 21: United States Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 22: United States Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 23: United States Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 24: Canada Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 25: Canada Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 26: Canada Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 27: Canada Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 28: Canada Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 29: Mexico Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 30: Mexico Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 31: Mexico Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 32: Mexico Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 33: Mexico Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 34: Europe Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 35: Europe Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 36: Europe Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 37: Europe Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 38: Europe Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 39: Europe Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Country, By Value, 2018-2028F
• Figure 40: Germany Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 41: Germany Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 42: Germany Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 43: Germany Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 44: Germany Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 45: France Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 46: France Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 47: France Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 48: France Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 49: France Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 50: United Kingdom Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 51: United Kingdom Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 52: United Kingdom Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 53: United Kingdom Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 54: United Kingdom Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 55: Italy Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 56: Italy Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 57: Italy Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 58: Italy Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 59: Italy Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 60: Spain Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 61: Spain Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 62: Spain Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 63: Spain Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 64: Spain Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 65: Asia Pacific Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 66: Asia Pacific Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 67: Asia Pacific Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 68: Asia Pacific Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 69: Asia Pacific Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 70: Asia Pacific Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Country, By Value, 2018-2028F
• Figure 71: China Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 72: China Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 73: China Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 74: China Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 75: China Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 76: Japan Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 77: Japan Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 78: Japan Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 79: Japan Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 80: Japan Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 81: India Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 82: India Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 83: India Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 84: India Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 85: India Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 86: South Korea Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 87: South Korea Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 88: South Korea Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 89: South Korea Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 90: South Korea Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 91: Australia Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 92: Australia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 93: Australia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 94: Australia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 95: Australia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 96: Singapore Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 97: Singapore Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 98: Singapore Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 99: Singapore Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 100: Singapore Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 101: Middle East & Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 102: Middle East & Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 103: Middle East & Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 104: Middle East & Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 105: Middle East & Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 106: Middle East & Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Country, By Value, 2018-2028F
• Figure 107: UAE Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 108: UAE Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 109: UAE Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 110: UAE Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 111: UAE Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 112: Saudi Arabia Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 113: Saudi Arabia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 114: Saudi Arabia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 115: Saudi Arabia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 116: Saudi Arabia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 117: South Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 118: South Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 119: South Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 120: South Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 121: South Africa Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 122: South America Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 123: South America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 124: South America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 125: South America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 126: South America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 127: South America Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Country, By Value, 2018-2028F
• Figure 128: Brazil Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 129: Brazil Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 130: Brazil Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 131: Brazil Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 132: Brazil Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 133: Argentina Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 134: Argentina Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 135: Argentina Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 136: Argentina Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 137: Argentina Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 138: Colombia Peripheral Blood Mononuclear Cells Market (PBMCs) Size, By Value (USD Billion), 2018-2028F
• Figure 139: Colombia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Product, By Value, 2018-2028F
• Figure 140: Colombia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Application, By Value, 2018-2028F
• Figure 141: Colombia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Technique, By Value, 2018-2028F
• Figure 142: Colombia Peripheral Blood Mononuclear Cells Market (PBMCs) Share, By Source, By Type, By Value, 2018-2028F
• Figure 143: Global Percentage of Cell and Gene Therapy Clinical Trials as of 2019, Divided by Clinical Trial Phase
• Figure 144: Peripheral Blood Mononuclear Cells: Breakdown of Pipeline, By Development Phase, 1992-2023
• Figure 145: Peripheral Blood Mononuclear Cells: Breakdown of Pipeline, By Status, 1992-2023
• Figure 146: Peripheral Blood Mononuclear Cells: Breakdown of Pipeline, By Study Type, 1992-2023
• Figure 147: Peripheral Blood Mononuclear Cells: Breakdown of Pipeline, By Region, 1992-2023
• Figure 148: Peripheral Blood Mononuclear Cells: Breakdown of Pipeline, By Year, 2017-2023
• Figure 149: Peripheral Blood Mononuclear Cells: Clinical Trials Heat Map

List of Tables

• Table 1: Global Cancer Statistics, 2020
• Table 2: Total Number of New Cancer Cases and Deaths Reported Globally, By Type, 2020
• Table 3: North America Cancer Statistics, 2020
• Table 4: Total Number of New Cancer Cases and Deaths Reported in North America, By Type, 2020
• Table 5: Europe Cancer Statistics, 2020
• Table 6: Total Number of New Cancer Cases and Deaths Reported in Europe, By Type, 2020
• Table 7: Asia Pacific Cancer Statistics, 2020
• Table 8: Total Number of New Cancer Cases and Deaths Reported in Asia Pacific, By Type, 2020
• Table 9: Middle East & Africa Cancer Statistics, 2020
• Table 10: Total Number of New Cancer Cases and Deaths Reported in Middle East & Africa, By Type, 2020
• Table 11: South America Cancer Statistics, 2020
• Table 12: Total Number of New Cancer Cases and Deaths Reported in South America, By Type, 2020
• Table 13: Pricing Analysis of PBMC Products
• Table 14: Clinical Trial Analysis

Global peripheral blood mononuclear cells market was valued at USD 235.68 million in 2022 and is anticipated to grow at a CAGR of 10.39% during the period 2023-2028 owing to the rising rate in the number of cell therapies, high demand of research, and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products. For instance, in June 2023, a study published in the National Library of Medicine assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.

Peripheral blood mononuclear cells (PBMCs) are a type of blood cell that plays a crucial role in the immune system. PBMCs are a heterogeneous population of cells that are isolated from the peripheral blood, which is the blood circulating throughout the body. They are composed of lymphocytes, monocytes, and other immune cells. Lymphocytes are a type of white blood cell that includes T cells, B cells, and natural killer (NK) cells. T cells are responsible for cell-mediated immune responses, B cells produce antibodies for humoral immune responses, and NK cells are involved in the innate immune system and killing infected or cancerous cells. Monocytes are another type of white blood cell that circulates in the bloodstream and can differentiate into macrophages or dendritic cells when they migrate into tissues. Macrophages are responsible for engulfing and destroying foreign substances, dead cells, and cellular debris, while dendritic cells play a critical role in initiating and regulating immune responses by presenting antigens to T cells. The isolation and characterization of PBMCs have revolutionized the understanding of the immune system and have contributed to advancements in various fields, including cancer research, infectious diseases, autoimmune disorders, and transplantation medicine.

PBMCs are widely used in various research applications, including immunology, cell therapy, vaccine development, and drug discovery. They provide valuable insights into immune responses, allow researchers to study various immune cell populations, and serve as a source of cells for cell-based therapies. PBMCs can be isolated from peripheral blood using techniques such as density gradient centrifugation or specialized cell separation methods.

Additionally, the rise in number of cell therapies, expansion in research & development schemes, increasing focus of key players on R&D in peripheral blood mononuclear cells, increasing focus on regenerative medicine, as well as an increase in demand for cell operations among the population, increasing investigation of various aspects of immunology, infectious diseases, autoimmune disorders, transplantation, and vaccine development are projected to provide market players with lucrative prospects in the future.

Growing Advancement for Toxicology Research

The growing awareness of customers for peripheral blood mononuclear cells, as well as a growing preference for antibody development, are two important growth drivers for the industry. PBMC is crucial to carry out biology and pathology-related studies as well as in clinical research related to fatal diseases, immunology, vaccine development, etc. For instance, according to clinicaltirals.gov.in, 972 studies have been carried out for peripheral blood mononuclear cells. PBMCs provide information on the effects of prospective novel medication molecules on people, particularly on their immune systems. Drug toxicity that affects PBMCs can result in several serious, sometimes fatal toxic side effects, including immune system suppression and poisoning. Toxicology research aims to evaluate the potentially harmful effects of chemical substances, drugs, and environmental factors on living organisms. PBMCs are used in immunotoxicity studies to assess the impact of these substances on the immune system. By exposing PBMCs to different compounds and analyzing immune responses, researchers can determine the immunotoxic effects, including alterations in immune cell populations, cytokine production, and immune function. The demand for PBMCs in immunotoxicity research is thus increasing, contributing to the growth of the global peripheral blood mononuclear cells market.

Increasing Importance of Peripheral Blood Mononuclear Cells for Cell Therapy

Patients now have a better alternative to cell-based therapies with respect to traditional regenerative medicines, but their side effects have hindered their use among customers. In this product category, developed regions such as North America and Europe have a strong presence in cell therapies for human well-being. The population is gaining awareness regarding the use of peripheral blood mononuclear cells in cell and gene therapy. Hence, the extraction and usage of peripheral blood mononuclear cells prove to be the key driving force for market expansion. However, fatal diseases such as acute myocardial infarction, chronic heart failure, spinal cord injury, stroke, and wound healing have all been successfully treated in pre-clinical studies using the secretome of apoptotic peripheral blood mononuclear cells, which drives the market growth globally. For instance, according to the Centers for Disease Control and Prevention, around 37,300 new cases of HPV+ tumors occur each year in the U.S., accounting for 3% of all malignancies in women and 2% of all cancers in men. With the increasing prevalence of HPV in the country, companies are continuously focusing on the development of therapy and drugs to enter the US market. PBMCs serve as a valuable source of immune cells for cell therapy. They contain various types of immune cells, including T cells, B cells, and natural killer (NK) cells, which play crucial roles in immune responses and disease targeting. PBMCs provide a diverse population of immune cells that can be isolated, manipulated, and utilized in different cell therapy approaches.

Also, Adoptive Cell Transfer (ACT) is a type of cell therapy that involves the transfer of immune cells, typically T cells, into patients to target and eliminate diseases, such as cancers. PBMCs are often used as a starting material to isolate and expand specific subsets of T cells, such as tumor-infiltrating lymphocytes (TILs), tumor-associated antigen-specific T cells, or genetically engineered T cells. PBMCs provide a convenient source of T cells for ACT therapies.

Growing Investment in Research & Development for Human Well-Being

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market as novel cell/gene therapies/medications and new products are developed for the treatment of fatal diseases. PBMCs are a reasonable way to acquire physiologically relevant (immune) proteins from routinely collected blood samples, and they do so without the native human plasma's well-known analytical challenges brought on by the presence of highly abundant proteins for driving the growth of the market. Furthermore, the government of different countries, for their growth in the healthcare sector, are providing funds for the ongoing research of peripheral blood mononuclear cells.

Additionally, the growing awareness of the potential of PBMCs in disease research has led to increased R&D activities and contributed to market growth. PBMCs play a crucial role in drug discovery and development. They are utilized in early-stage research to assess the efficacy and safety of potential drug candidates. PBMCs provide a human-relevant model for studying immune responses and evaluating the effects of new compounds on immune cells. The growing awareness of the value of PBMCs in drug discovery has resulted in increased demand and utilization of these cells, driving the growth of the PBMCs market. The awareness of the therapeutic potential of cell-based therapies has been growing rapidly. PBMCs are essential in the development and manufacturing of cell-based therapies, such as adoptive cell transfer, CAR-T cell therapy, and immunotherapies. The therapeutic benefits of these advanced therapies, coupled with the increasing awareness of PBMCs' role in their development, have led to significant R&D efforts and the growth of global peripheral blood mononuclear cells market. There has been a notable increase in collaboration between academic institutions, research organizations, and the biopharmaceutical industry. This collaboration has fostered knowledge exchange, joint research projects, and funding initiatives focused on the application of PBMCs in various areas of research. The growing awareness of the potential of PBMCs and the collaborative efforts in R&D have positively impacted the growth of the global peripheral blood mononuclear cells market.

Market Segmentation

The global peripheral blood mononuclear cells market is segmented based on product, application, technique, source, region, and competitive landscape. Based on the product, the market can be split into cryopreserved or frozen PBMC, cultured or fresh PBMC, and peripheral blood mononuclear cell isolation & viability kits. Based on application, the market can be divided into immunology, hematology, infectious disease, and others. Based on techniques, the market is divided into density gradient centrifugation, leukapheresis, and others. In terms of sources, the market can be categorized into humans and animals.

Company Profiles

Charles River Laboratories International, Inc., Lonza Group AG, Corning Inc, Bio-Rad Laboratories Inc, ABCAM, Biolegend Inc, ZEN-Bio Inc, DAPCEL, Inc., Creative Bioarray, iXCells Biotechnologies USA, LLC, Miltenyi Biotec B.V. & CO. KG, STEMCELL Technologies Inc., Precision Medicine Group, LLC, StemExpress, LLC, RayBiotech Life, Inc., REPROCELL Inc., Cytologics LLC, BioIVT LLC, Biopredic International, and Cell Applications, Inc. etc. are among the major players in the global peripheral blood mononuclear cells market.

Report Scope:

In this report, Global Peripheral Blood Mononuclear Cells Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Peripheral Blood Mononuclear Cells Market, By Product:

• Cryopreserved or Frozen PBMC
• Cultured or Fresh PBMC
• Others

Peripheral Blood Mononuclear Cells Market, By Application:

• Immunology
• Hematology
• Infectious Disease
• Others

Peripheral Blood Mononuclear Cells Market, By Techniques:

• Density Gradient Centrifugation
• Leukapheresis
• Others

Peripheral Blood Mononuclear Cells Market, By Source:

• Human
• Animal

Peripheral Blood Mononuclear Cells Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global peripheral blood mononuclear cells market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Peripheral Blood Mononuclear Cells Market

5. Voice of Customer

• 5.1. By Type of Product
• 5.2. By Type of Technique
• 5.3. Type of Application for Which PBMCs Are Used
• 5.4. Factors Driving Market Growth

6. Global Peripheral Blood Mononuclear Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC and Peripheral Blood Mononuclear Cell Isolation & Viability Kits)
  • 6.2.2. By Application (Immunology, Infectious Disease, Hematology and Others)
  • 6.2.3. By Technique (Density Gradient Centrifugation Process and Leukapheresis)
  • 6.2.4. By Source (Human and Animals)
  • 6.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 6.2.6. By Company (2021)
• 6.3. Market Map
  • 6.3.1. By Product
  • 6.3.2. By Application
  • 6.3.3. By Technique
  • 6.3.4. By Source
  • 6.3.5. By Region

7. North America Peripheral Blood Mononuclear Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technique
  • 7.2.4. By Source
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technique
      • 7.3.1.2.4. By Source
  • 7.3.2. Canada Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technique
      • 7.3.2.2.4. By Source
  • 7.3.3. Mexico Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technique
      • 7.3.3.2.4. By Source

8. Europe Peripheral Blood Mononuclear Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technique
  • 8.2.4. By Source
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technique
      • 8.3.1.2.4. By Source
  • 8.3.2. France Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technique
      • 8.3.2.2.4. By Source
  • 8.3.3. United Kingdom Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technique
      • 8.3.3.2.4. By Source
  • 8.3.4. Italy Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technique
      • 8.3.4.2.4. By Source
  • 8.3.5. Spain Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technique
      • 8.3.5.2.4. By Source

9. Asia-Pacific Peripheral Blood Mononuclear Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technique
  • 9.2.4. By Source
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technique
      • 9.3.1.2.4. By Source
  • 9.3.2. Japan Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technique
      • 9.3.2.2.4. By Source
  • 9.3.3. India Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technique
      • 9.3.3.2.4. By Source
  • 9.3.4. South Korea Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product
      • 9.3.4.2.2. By Application
      • 9.3.4.2.3. By Technique
      • 9.3.4.2.4. By Source
  • 9.3.5. Australia Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Product
      • 9.3.5.2.2. By Application
      • 9.3.5.2.3. By Technique
      • 9.3.5.2.4. By Source

10. South America Peripheral Blood Mononuclear Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Technique
  • 10.2.4. By Source
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technique
      • 10.3.1.2.4. By Source
  • 10.3.2. Argentina Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technique
      • 10.3.2.2.4. By Source
  • 10.3.3. Colombia Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technique
      • 10.3.3.2.4. By Source

11. Middle East and Africa Peripheral Blood Mononuclear Cells Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Product
  • 11.2.2. By Application
  • 11.2.3. By Technique
  • 11.2.4. By Source
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. UAE Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Product
      • 11.3.1.2.2. By Application
      • 11.3.1.2.3. By Technique
      • 11.3.1.2.4. By Source
  • 11.3.2. Saudi Arabia Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Product
      • 11.3.2.2.2. By Application
      • 11.3.2.2.3. By Technique
      • 11.3.2.2.4. By Source
  • 11.3.3. South Africa Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Product
      • 11.3.3.2.2. By Application
      • 11.3.3.2.3. By Technique
      • 11.3.3.2.4. By Source

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

14. Clinical Trial Analysis

• 14.1. Ongoing Clinical Trials
• 14.2. Completed Clinical Trials
• 14.3. Terminated Clinical Trials
• 14.4. Breakdown of Pipeline, By Development Phase
• 14.5. Breakdown of Pipeline, By Status
• 14.6. Breakdown of Pipeline, By Study Type
• 14.7. Breakdown of Pipeline, By Region
• 14.8. Clinical Trials Heat Map

15. Competitive Landscape

• 15.1. Competitive Outlook
• 15.2. Company Profiles
  • 15.2.1. Charles River Laboratories International, Inc.
  • 15.2.2. Lonza Group AG
  • 15.2.3. Corning Inc
  • 15.2.4. Bio-Rad Laboratories Inc
  • 15.2.5. ABCAM
  • 15.2.6. Biolegend Inc
  • 15.2.7. ZEN-Bio Inc
  • 15.2.8. DAPCEL, Inc.
  • 15.2.9. Creative Bioarray
  • 15.2.10. iXCells Biotechnologies USA, LLC
  • 15.2.11. Miltenyi Biotec B.V. & CO. KG
  • 15.2.12. STEMCELL Technologies Inc.
  • 15.2.13. Precision Medicine Group, LLC.
  • 15.2.14. StemExpress, LLC
  • 15.2.15. RayBiotech Life, Inc.
  • 15.2.16. REPROCELL Inc.
  • 15.2.17. Cytologics LLC
  • 15.2.18. BioIVT LLC
  • 15.2.19. Biopredic International
  • 15.2.20. Cell Applications, Inc.

16. Strategic Recommendations

17. TechSci Research - Awards and Recognition

18. About Us & Disclaimer